Overview

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Status:
Completed

Trial end date:
2004-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.

Phase:

Phase 3

Details

Lead Sponsor:

Alcon Research

Treatments:

Latanoprost
Travoprost